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UPDATE Open Access
Does intermittent pneumatic compression reduce
the risk of post stroke deep vein thrombosis? The
CLOTS 3 trial: statistical analysis plan
Martin Dennis1*, Peter Sandercock1, Gordon Murray2, John Forbes2 and on behalf of The CLOTS Trials
Collaboration
Abstract
Background: Venous thromboembolism (VTE) is a common and important complication of stroke. The CLOTS 3
trial aims to determine whether, compared with best medical care, best medical care plus intermittent pneumatic
compression (IPC) in immobile stroke patients reduces the risk of proximal deep vein thrombosis (DVT).
Methods/Design: The CLOTS 3 trial is a multicenter, parallel group trial with centralized randomization
(minimization) to ensure allocation concealment. The protocol has been published (Trials 2012, 13:26) and is
available in full at: http://www.clotstrial.com. Between December 2008 and September 2012, 105 centers in the UK
recruited 2,876 immobile stroke patients within the first 3 days of their hospital admission. Patients were allocated
to best medical care or best medical care plus IPC. Ultrasonographers performed a compression Doppler ultrasound
scan to detect DVT in each treatment group at 7 to 10 days and 25 to 30 days. The primary outcome cluster
includes symptomatic or asymptomatic DVT in the popliteal or femoral veins detected on either scan. Patients will
be followed up by postal or telephone questionnaire at 6 months from randomization to detect later symptomatic
DVT and pulmonary embolism (PE), and to measure functional outcome (Oxford Handicap Scale) and quality of life
(EQ-5D-3L). The ultrasonographers performing the scans are blinded to treatment allocation, whereas the patients
and caregivers are not. The trial has more than 90% power to detect a 4% absolute difference (12% versus 8%) in
risk of the primary outcome and includes a health economic analysis.
Follow-up will be completed in April 2013 and the results reported in May 2013. In this update, we describe the
statistical analysis plan.
Trial registration: ISRCTN: ISRCTN93529999
Keywords: Stroke, Deep vein thrombosis, Prevention, Intermittent pneumatic compression, Statistical analysis plan
Update
Introduction
A description of the CLOTS 3 trial protocol has already
been published [1] and that article contained a brief
description of planned analyses. However, to avoid criticism
that our analyses are post hoc or data driven, we have
published this more detailed statistical analysis plan in
advance of closing the database and performing analyses.
None of the authors of this analysis plan have had access
to any interim analyses which split the patients by treat-
ment group. The trial statistician who prepared the
interim analyses for the independent data monitoring
committee (DMC) was not involved in the writing of
this analysis plan.
The overall analysis strategy is similar to that reported
in the published CLOTS 1 and 2 trials [2,3].
Before describing the planned analyses, the key meth-
odological features of the CLOTS 3 trial will be presented.
It is a multicenter, parallel group trial with centralized
randomization (minimization) and 1:1 allocation to ensure
allocation concealment.* Correspondence: martin.dennis@ed.ac.uk1Division of Clinical Neurosciences, The University of Edinburgh, Western
General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Full list of author information is available at the end of the article
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Primary research question in the CLOTS 3 trial
Does early and routine application of intermittent
pneumatic compression (IPC), in addition to routine
care, reduce the risk of above knee deep vein thrombosis
(DVT) in the weeks following an acute stroke?
Minimization algorithm
A minimization program is used to achieve optimum
balance for the following important prognostic factors:
1. Delay since stroke onset (day 0 or 1 versus day 2 to 7).
2. Stroke severity (using a validated prognostic model
[4], which includes the factors: age, pre-stroke
dependency in activities of daily living (ADL), living
with another person prior to stroke, able to talk and
orientated in time, place and person, and able to lift
both arms to horizontal position against gravity).
3. Severity of leg paresis (able, or not, to lift leg off
the bed).
4. Use of heparin, warfarin or thrombolysis
(recombinant tissue plasminogen activator (rtPA)) at
time of enrolment.
Primary outcome
The primary outcome is the presence of definite or
probable symptomatic or asymptomatic DVT in the
popliteal or femoral veins detected on compression
Doppler ultrasound scan, or any symptomatic DVT in
the popliteal or femoral veins confirmed on compression
Doppler ultrasound, contrast venography or MRI direct
thrombus imaging within 30 days of randomization.
Secondary outcomes
The secondary outcomes are:
1. Presence of definite or probable DVT in the
popliteal or femoral veins detected on a screening
compression Doppler ultrasound scan, which was
not clinically suspected before the scan.
2. Definite (excluding probable DVTs) symptomatic
or asymptomatic DVT in the popliteal or
femoral veins detected on compression Doppler
ultrasound scan, contrast venography or MRI
direct thrombus imaging within 30 days of
randomization.
3. Any definite or probable symptomatic or
asymptomatic DVT (including DVTs, which only
involve the calf veins).
4. Confirmed fatal or non-fatal pulmonary embolism
(PE).
5. Adherence to allocated treatment.
6. Adverse events related to IPC within 30 days of
randomization.
7. Patient death within 30 days of randomization.
Secondary outcomes at 6 months
The secondary outcomes at 6 months are:
1. Any confirmed symptomatic or asymptomatic DVT
or PE occurring between randomization and final
follow-up.
2. Any symptomatic DVT or PE occurring between
randomization and final follow-up.
3. Place of residence.
4. Post DVT syndrome.
5. Disability (Oxford Handicap Scale (OHS) [5], simple
questions [6]).
6. Health-related quality of life (EQ-5D-3L, EuroQol,
Rotterdam, The Netherlands [7]).
7. Death from any cause.
The later effects of DVT/PE (for example breathlessness,
leg pain, leg swelling and poor stroke recovery) or the
adverse events related to IPC (falls with injury, fractures,
skin ulceration, amputation and loss of mobility) may be
diverse; therefore, a measure of overall health-related
quality of life is included.
Adverse events
The adverse events are:
1. Any damage to the skin of the legs including
necrosis and ulcers occurring within 30 days of
enrollment.
2. Any reasons for prematurely stopping the IPC.
3. Any fall associated with significant injury occurring
within 30 days of enrollment (when IPC might still be
applied). These are injuries that require investigation,
specific treatment, prolong hospitalization, or lead to
temporary or permanent disability, or death.
4. Fractures.
Follow-up
Patients will have a compression Doppler ultrasound
scan examination of the veins in both legs between day
7 and 10, and between day 25 and 30. This examination
will document thrombus in the calf, popliteal and femoral
veins separately.
The data collected at discharge will include:
1. Use of heparin, warfarin and antiplatelet drugs
during admission, to monitor the components of
routine care and to ensure equal use in the two
treatment arms. The indication for the use of
anticoagulants is recorded.
2. Use of full length or below knee graduated
compression stockings, to monitor the components
of routine care and to ensure equal use in the two
treatment arms.
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3. Timing of initiation of IPC, adherence to treatment
allocation and use of IPC. If IPC is prematurely
stopped, the reason is recorded.
4. Any clinical DVT or PE.
5. Any treatment complications, in particular skin
problems with legs and falls resulting in injuries,
occurring within the first 30 days after enrolment.
Follow-up at 6 months
For patients who have been discharged, outcome will be
assessed via a postal or telephone questionnaire to establish:
1. That the patient is alive; or, if applicable, the date
and cause of death.
2. Whether the patient has suffered a DVT or PE since
discharge.
3. The place of residence (own home, with relatives,
residential care or nursing home), as a guide to
resource use.
4. Functional status measured by the degree of
functional impairment on the OHS, simple questions
and health-related quality of life using EQ-5D-3L.
5. Current antithrombotic medication regimen.
6. Presence of symptoms which might reflect post DVT
syndrome (for example leg swelling and ulcers).
Ethical Approval
The protocol was approved by the Multicentre Research
Ethics committees (in Scotland and England). Informed
consent was obtained from all participants, or if they
lack capacity, from a personal legal representative.
Statistical analysis plan
All analyses will be based on intention-to-treat. We will
analyze patients in the groups they were randomized to,
regardless of treatment received. We will strive to obtain
full follow-up data on every patient to allow a full
intention-to-treat analysis, but inevitably some patients
will be lost to follow-up. We will exclude these patients
from the analyses with no data and undertake sensitivity
analyses to examine the effect of exclusions on the
conclusions. For binary outcomes (for example occurrence,
or not, of a primary or secondary outcome), outcomes will
be presented as odds ratios and 95% confidence intervals
(CIs), adjusted using logistic regression for the factors used
in the minimization algorithm. We will calculate absolute
reductions in risk from these values along with 95% CIs.
Primary analysis
The primary analysis will aim to establish whether a
policy of early routine application of IPC to immobile
stroke patients, within the first 3 days of hospital admission
and within 7 days of the stroke onset, reduces the frequency
of the primary outcome (symptomatic or asymptomatic
DVT within 30 days). This will compare the occurrence of
the primary outcome in the two arms of the trial. Patients
in each arm will be categorized as:
1. Alive no DVT (no primary outcome).
2. Alive with DVT (primary outcome).
3. Died prior to any primary outcome.
4. Missing.
The primary analysis will compare IPC with no IPC for
the occurrence of DVT (death and missing excluded),
adjusted for the variables included in the minimization
algorithm by logistic regression. The treatment effect will
be presented as an odds ratio with 95% CIs. We will give a
P value and change in −2 log-likelihood. We will also
present unadjusted estimates.
In addition, we will perform a sensitivity analysis
comparing IPC with no IPC for the occurrence of DVT
(with death counted as DVT and missing as no DVT).
Secondary analyses
Minimizing observer bias
Although we strive to blind the radiographer to the
treatment allocation, our primary outcome may be
prone to observer bias. For example, if a patient presents
clinical signs of DVT, the ward staff may push harder to
obtain the routine compression Duplex ultrasound scan.
We will therefore repeat the primary analysis but
exclude patients with a primary outcome in whom a DVT
was suspected before the ultrasound scan.
Safety
There are a number of adverse events that might occur with
IPC use. For example IPC might increase the risk of PE by
squeezing the leg in patients who have already developed a
DVT; patients who attempt to mobilize with the IPC
sleeves attached might fall and suffer injury; or the sleeves
or intermittent pressure may cause patients to develop skin
breaks on their legs. Any of these events could be fatal.
We will therefore compare the occurrence of the
following events within 30 days of randomization in
the IPC and no IPC groups: death from any cause,
confirmed PE (fatal or non-fatal), skin breaks, fall with
injury and fractures.
Subtypes of venous thrombembolism
It is possible that IPC may reduce the frequency of one type
of venous thrombembolism (VTE) (for example below knee
DVT) whilst increase the risk of another (for example PE).
We will therefore repeat our primary analysis and
subcategorize VTE as:
1. Any DVT (symptomatic or asymptomatic DVT,
affecting calf only and/or proximal veins occurring
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within 30 days or by second compression Doppler
ultrasound scan).
2. Only symptomatic DVT (defined as associated with
leg swelling, pain or warmth) whether affecting
proximal veins or calf only occurring within 30 days.
3. Confirmed fatal or non-fatal PE occurring within
30 days.
Subgroup analyses
Subgroup analyses will be performed to determine
whether certain types of patients might gain greater or
less benefit from IPC. We will estimate the effect of
treatment allocation on the primary outcome subdivided
by key baseline variables and adjusted for the other factors
included in the minimization algorithm. Subgroup analyses
will be performed by observing the change in log-likelihood
when the interaction between the treatment and the
subgroup is added into a logistic regression model. We
will determine whether there is significant heterogeneity
between these subgroups.
Analysis of impact of delay in applying IPC
There is evidence that DVTs may develop within the
first 3 days after a stroke [8]. There is often a delay in
presenting with a stroke and there will always be a delay
in applying VTE prophylaxis, since the patients need to
be assessed and the treatment started. In addition, in a
randomized trial there may be additional delays owing to
the time taken to obtain consent and enroll the patients.
To reduce the possible impact of this delay, we encourage
collaborators to enroll patients as early as possible after
admission and stipulated that at least 75% of patients are
enrolled within day 0 (day of stroke) and day 2.
We hypothesize that IPC will reduce the frequency of
the primary outcome to a greater extent among patients
enrolled early compared to later. We will therefore
examine the effect of treatment among patients enrolled
early versus later. We will also assess the effect of delay
by applying two different definitions of delay (measured
in days from stroke onset to enrolment): day 0 to 1 versus
day 2 to 7 (the split on which the minimization algorithm
is based), and day 0 to 2 versus day 3 to 7 (as stipulated in
the sample size estimates).
Other preplanned subgroup analyses, described in our
original protocol, include analyses of the effect of treatment
on the primary outcome subdivided by: paralysis of leg
(able to lift both legs versus unable to lift both legs) at
randomization and probability of survival free of
dependency (OHS <3) based on the predictive model
used in minimization.
We hypothesize that patients with predicted worse
outcomes have higher rates of DVT because of more
prolonged immobility and the co-occurrence of infections.
Also, this group may have better adherence to the IPC,
since these patients are not as able to express a wish to
have them removed.
Is IPC more effective in patients at higher risk of DVT?
It seems likely that patients at higher risk of DVT might
gain greater benefit from IPC than those at lower risk.
In the CLOTS 1 and 2 trials, we showed that immobile
stroke patients with the following features had a greater
risk of proximal DVT [9]: dependent in ADL prior to
stroke, prior history of DVT, unable to lift both arms
and unable to lift both legs. We will undertake subgroup
analyses of the effect of allocation to IPC on the primary
outcome among patients with and without at least one
of these factors at baseline.
Is IPC more effective in patients in whom anticoagulation is
not given or advisable?
In some health systems anticoagulation is widely used
for the prophylaxis of DVT in patients with ischaemic
stroke despite the lack of evidence that it improves
overall outcome. Consequently, IPC and other forms of
compression have often been used in patients with
hemorrhagic stroke. We will therefore carry out the
following subgroup analyses of patients on anticoagulants
(as defined in our protocol [1]) versus not at baseline and
with confirmed hemorrhagic versus ischaemic or unknown
pathological type of stroke.
Duration and intensity of treatment with IPC
IPC has usually been used for a relatively short time on
perioperative patients and patients in high dependency
units. In the CLOTS 3 trial, we aimed to maintain the
IPC treatment for up to 30 days, if the patient remained
in hospital and was still immobile. However, for a variety
of reasons, the IPC was often removed earlier than this or
was applied non-continuously. In CLOTS 1 and 2 trials,
79% of proximal DVTs were detected on the first compres-
sion Doppler ultrasound scan [10]. The risk of DVT seemed
to be highest early on and therefore any prophylaxis might
be more effective during this period.
We will therefore carry out additional analyses
(including all those subgroups identified in the primary
outcome) of the effect of allocation to IPC on the primary
outcome occurring within 14 days of randomization,
rather than 30 days. This will, to some extent, reduce the
impact of patients who only required IPC for a few days
before becoming mobile or only adhered to IPC for a
short time. Also, it will reflect the practice in many places
where acute hospital admission for stroke is short and
prophylaxis is only applied for the first few days. However,
it is also possible that prophylaxis for the first 7, 14 or
30 days may simply defer the onset of DVT. We will
therefore analyze whether there is a difference in fre-
quency of any symptomatic and/or asymptomatic DVT
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or PE within 6 months between patients allocated to
IPC, or not.
During the CLOTS 3 trial, it was noted that adherence
to the IPC was suboptimal. The manufacturer responded to
this information by introducing a modified IPC sleeve, the
Kendall™ SCD Sequential Compression Comfort Sleeves,
which aimed to improve acceptability and adherence. We
switched to using this new sleeve on 17th October 2011.
Therefore, the first 1679 (approximately 59%) patients
enrolled in the CLOTS 3 trial were allocated to the original
sleeve, or not; and the subsequent patients to the Comfort
sleeve, or not. We will therefore examine the effect of the
original and Comfort sleeves separately. We will also
compare the adherence to the sleeves, which will be based
on a non-randomized comparison.
If primary analyses fail to demonstrate a reduction of DVT
with IPC, is this likely to be due to poor adherence?
If the primary or secondary analyses do not provide
evidence that IPC reduces the risk of DVT, we will perform
further analyses to establish the extent to which poor
adherence to the IPC might explain this lack of effect.
We will build a statistical model based on baseline factors
in the IPC group to predict the degree of adherence to IPC.
We will then use this model to dichotomize patients in
both groups at baseline into patients likely to have high
and low adherence. We will then examine whether the
effect is greater in patients with a likelihood of better
adherence to IPC.
Overall benefit
Although the primary aim of the CLOTS 3 trial is to
establish whether IPC reduces the risk of post stroke
DVT, it is also important to determine whether it
improves overall outcome [11]. However, the CLOTS 3
trial was not powered to establish whether IPC influences
longer-term outcome. We will, however, compare the
following longer-term outcomes in patients allocated
IPC, or not, adjusted for baseline factors in the same
way as the primary analyses:
1. Survival to 6 months (Cox proportional hazards model).
2. Living circumstances at final follow-up (living at
home versus living in an institution/still in hospital).
3. Death, dependent, independent but with problems
or no problems (assessed by simple questions).
4. OHS at final follow-up, analyzed in two ways:
dichotomized in OHS 0 to 2 versus 3 to 6
(by logistic regression) and as an ordinal scale
(by ordinal regression).
5. Health-related quality of life (measured by EQ-5D-3L).
The utility based on the EQ-5D-3L will be compared
by t-tests if the data are normally distributed and use an
appropriate nonparametric test otherwise. The EQ-5D-3L
data will be analyzed in two ways: one excluding the
patients who died and for whom we do not have 6 month
EQ-5D-3L; and the other which includes the patients who
have died, giving them a utility of 0, but excluding those
with missing data.
Economic analyses
Economic analysis of trial treatment effects will involve
a within-trial evaluation of cost effectiveness integrated
into a decision-analytic model of longer run costs and
health effects. The within-trial analysis will be conducted
on an intention-to-treat basis. The primary health end-
points will be survival times adjusted for quality of life.
A standard multiplicative model will be used to estimate
quality adjusted life years (QALYs) by the area under
linear interpolation of the EQ-5D-3L index trajectory for
each individual patient using survival times, the EQ-5D-
3L index score at 6 months and a modeled baseline EQ-
5D-3L index score. We will assess robustness using
probabilistic sensitivity analysis of the parameters used
to generate the short-run QALY estimates.
A NHS perspective will be adopted for assessing
resource use and costs. Patient-specific hospital resource
use will be measured using the duration of stay for the
index episode following randomization. The net direct
medical cost will include the hospital stay, converted
into cost estimates using NHS per diem hospital costs, a
cost estimate of IPC capital/equipment (and staffing
implications) and the averted costs arising from the
effects of IPC on expected DVT/PE incidence. Trial centre
or region-specific per diem hospital costs will be based on
NHS reference costs in England and cost information for
NHS Scotland derived from the Scottish Health Service
Costs resource. Probabilistic sensitivity analysis will also
be used to assess the hospital cost distributions.
We will assess differences in costs and effects using
econometric methods based on a copula framework,
which is particularly useful and straightforward when
modeling joint parametric distributions. We will also
summarize the cost effectiveness results within a net
benefit approach using incremental net (monetary) benefit
and cost-effectiveness acceptability curves.
Costs and benefits of an effective approach to preventing
DVT following stroke will accrue over time. An important
element of the economic analysis will be a focus on longer
run outcomes using a decision-analytic model that builds
on the within-trial findings. The key parameters for the
patient level simulation model will include expected
survival, quality of life, long-term complications, such as
post-thrombotic syndrome, and use of health services over
a 6-month to 5-year time horizon. The model will be
calibrated using distributions from reported systematic
reviews of survival and health-related quality of life
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following stroke and the long-term prognosis, and
cost burden of DVT in the community. Monte Carlo
probabilistic sensitivity analysis will be used to account for
uncertainty in the cost effectiveness results based on the
simulation model.
Other planned analyses
We will examine the association between baseline variables
and the occurrence of post stroke DVT. We will replicate
the analyses performed in the CLOTS 1 and 2 trials to
verify findings in those trials [9,10]. We will also examine
the strength of association between the occurrence of DVT
within the first 30 days and longer-term survival and OHS.
We will use this dataset to externally validate the
models previously developed by our group and used in
the minimization algorithm to predict the OHS at 6
months [4]. This dataset will also be used to externally
validate a statistical model that we have built in the
CLOTS 1 and 2 trial datasets to predict which patients
will respond to postal questionnaires at 6 months.
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